文献速递慢阻肺肺结节与肺癌

脂质运载蛋白-2升高与慢阻肺相关并抑制肺腺癌发生

Augmented Lipocalin-2 Is Associated with Chronic Obstructive Pulmonary Disease and Counteracts Lung Adenocarcinoma Development.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01

研究探讨脂质运载蛋白-2(LCN2)在慢阻肺相关肺腺癌(LUAD)中的作用。分析Gprc5a-/-小鼠及人类数据集发现,LCN2在LUAD发展过程中逐渐升高,且在吸烟者和LUAD患者中与慢阻肺相关。Gprc5a-/-/Lcn2-/-小鼠肺肿瘤发生显著增加,伴CD4+ T细胞减少和抗肿瘤免疫基因程序减弱,表明LCN2通过维持抗肿瘤免疫来抑制LUAD发展。

要点

  • LCN2在慢阻肺相关肺腺癌中特异性升高,可能作为分子标志物。
  • LCN2缺失促进肺肿瘤发生,与CD4+ T细胞减少和抗肿瘤免疫减弱相关。
  • LCN2可能通过维持抗肿瘤免疫来抑制肺腺癌发展。

核心结论

  • LCN2表达升高是慢阻肺相关肺腺癌的分子特征,并在体内通过维持抗肿瘤免疫来抑制LUAD发展。

研究设计与样本

  • 分析Gprc5a-/-小鼠(暴露烟草致癌物前后)的正常气道刷检、非肿瘤肺组织和肿瘤的RNA测序。
  • 分析公共和内部LUAD、LUSC、COPD及LUAD/LUSC合并COPD数据集中LCN2 mRNA表达。
  • 在510例肿瘤的组织微阵列中免疫组化分析LCN2蛋白。
  • 比较Gprc5a-/-与Gprc5a-/-/Lcn2-/-同窝小鼠的肺肿瘤发展、基因表达程序和宿主免疫应答。

主要发现

  • Lcn2在LUAD发展过程中逐渐升高,并与促炎细胞因子和炎症基因集正相关。
  • 相对于正常肺组织,LCN2在人LUAD中特异性升高,但在LUSC中未升高,且在吸烟者和LUAD患者中与COPD相关。
  • 与Gprc5a-/-小鼠相比,Gprc5a-/-/Lcn2-/-同窝小鼠肺肿瘤发展显著增加,伴CD4+ T细胞丰度和丰富度降低、抗肿瘤免疫基因程序减弱、免疫细胞促肿瘤炎性细胞因子表达增加。

临床怎么用

  • LCN2可能作为慢阻肺相关肺腺癌的分子标志物,用于风险分层或早期预警。
  • 增强LCN2通路或维持抗肿瘤免疫可能成为肺腺癌防治策略,但需进一步临床验证。

局限性

  • 研究主要基于小鼠模型和回顾性人体数据集,因果性需前瞻性研究验证。
  • LCN2在人体中的治疗靶向性和安全性尚未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Early pathogenesis of lung adenocarcinoma (LUAD) remains largely unknown. We found that, relative to wild-type littermates, the innate immunomodulator Lcn2 (lipocalin-2) was increased in normal airways from mice with knockout of the airway lineage gene Gprc5a (Gprc5a-/-) and that are prone to developing inflammation and LUAD. Yet, the role of LCN2 in lung inflammation and LUAD is poorly understood.Objectives: Delineate the role of Lcn2 induction in LUAD pathogenesis.Methods: Normal airway brushings, uninvolved lung tissues, and tumors from Gprc5a-/- mice before and after tobacco carcinogen exposure were analyzed by RNA sequencing. LCN2 mRNA was analyzed in public and in-house data sets of LUAD, lung squamous cancer (LUSC), chronic obstructive pulmonary disease (COPD), and LUAD/LUSC with COPD. LCN2 protein was immunohistochemically analyzed in a tissue microarray of 510 tumors. Temporal lung tumor development, gene expression programs, and host immune responses were compared between Gprc5a-/- and Gprc5a-/-/Lcn2-/- littermates.Measurements and Main Results:Lcn2 was progressively elevated during LUAD development and positively correlated with proinflammatory cytokines and inflammation gene sets. LCN2 was distinctively elevated in human LUADs, but not in LUSCs, relative to normal lungs and was associated with COPD among smokers and patients with LUAD. Relative to Gprc5a-/- mice, Gprc5a-/-/Lcn2-/- littermates exhibited significantly increased lung tumor development concomitant with reduced T-cell abundance (CD4+) and richness, attenuated antitumor immune gene programs, and increased immune cell expression of protumor inflammatory cytokines.Conclusions: Augmented LCN2 expression is a molecular feature of COPD-associated LUAD and counteracts LUAD development in vivo by maintaining antitumor immunity.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Treekitkarnmongkol W, Hassane M, Sinjab A, et al. Augmented Lipocalin-2 Is Associated with Chronic Obstructive Pulmonary Disease and Counteracts Lung Adenocarcinoma Development. Am J Respir Crit Care Med. 2021. PMID: 32730093. doi:10.1164/rccm.202004-1079OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。